Ian M Fearon1, Alison Eldridge2, Nathan Gale2, Christopher J Shepperd3, Mike McEwan3, Oscar M Camacho4, Mitch Nides5, Kevin McAdam6, Christopher J Proctor7. 1. Principal Scientist and Head of Clinical Research, British American Tobacco (Investments) Limited, Research and Development, Southampton, United Kingdom (UK). 2. Scientist II Clinical Research, British American Tobacco (Investments) Limited, Research and Development, Southampton, UK. 3. Senior Scientist Clinical Research, British American Tobacco (Investments) Limited, Research and Development, Southampton, UK. 4. Senior Statistician, British American Tobacco (Investments) Limited, Research and Development, Southampton, UK. 5. President, Los Angeles Clinical Trials, Burbank, CA. 6. Head of NGP Safety Assessment, British American Tobacco (Investments) Limited, Research and Development, Southampton, UK. 7. Chief Scientific Officer, British American Tobacco (Investments) Limited, Research and Development, Southampton, UK;, Email: ian_fearon@bat.com.
Abstract
OBJECTIVES: E-cigarettes could potentially play a major role in tobacco harm reduction by delivering nicotine in a vapor containing significantly fewer toxicants than cigarette smoke and may aid smoking behavior changes such as reduction or cessation. METHODS: We examined blood nicotine levels in smokers who were non-accustomed to e-cigarette use (Study 1) and accustomed e-cigarette users (Study 2). We compared nicotine levels when participants used a closed modular system e-cigarette to those when participants smoked a cigarette. RESULTS: In Study 1, Cmax (geometric mean (CV)) during a 5-minute puffing period (10 puffs, 30 seconds apart) was 13.4 (51.4) ng/ ml for a regular cigarette. The e-cigarette Cmax was significantly lower (p .05) at 2.5 (67.8) ng/ml. In Study 2, during a 5-minute ad libitum puffing period, cigarette Cmax was 7.2 (130.8) ng/mL, and it was 7.8 (108.2) ng/mL for the e-cigarette. CONCLUSIONS: Our data demonstrate heterogeneity of nicotine deliveries both between products and also with the same products used by different cohorts, eg, accustomed users versus smokers. Such differences must be taken into account when determining the likely behavioral impact, on smoking reduction and cessation, of nicotine delivery data and when planning e-cigarette nicotine pharmacokinetic studies.
OBJECTIVES: E-cigarettes could potentially play a major role in tobacco harm reduction by delivering nicotine in a vapor containing significantly fewer toxicants than cigarette smoke and may aid smoking behavior changes such as reduction or cessation. METHODS: We examined blood nicotine levels in smokers who were non-accustomed to e-cigarette use (Study 1) and accustomed e-cigarette users (Study 2). We compared nicotine levels when participants used a closed modular system e-cigarette to those when participants smoked a cigarette. RESULTS: In Study 1, Cmax (geometric mean (CV)) during a 5-minute puffing period (10 puffs, 30 seconds apart) was 13.4 (51.4) ng/ ml for a regular cigarette. The e-cigarette Cmax was significantly lower (p .05) at 2.5 (67.8) ng/ml. In Study 2, during a 5-minute ad libitum puffing period, cigarette Cmax was 7.2 (130.8) ng/mL, and it was 7.8 (108.2) ng/mL for the e-cigarette. CONCLUSIONS: Our data demonstrate heterogeneity of nicotine deliveries both between products and also with the same products used by different cohorts, eg, accustomed users versus smokers. Such differences must be taken into account when determining the likely behavioral impact, on smoking reduction and cessation, of nicotine delivery data and when planning e-cigarette nicotine pharmacokinetic studies.
Authors: Jenny E Ozga-Hess; Nicholas J Felicione; Stuart G Ferguson; Geri Dino; Daniel Elswick; Catherine Whitworth; Nicholas Turiano; Melissa D Blank Journal: Addict Behav Date: 2019-08-21 Impact factor: 3.913
Authors: Nathan Gale; Mike McEwan; Alison C Eldridge; Neil Sherwood; Edward Bowen; Simon McDermott; Emma Holmes; Andrew Hedge; Stuart Hossack; Oscar M Camacho; Graham Errington; John McAughey; James Murphy; Chuan Liu; Christopher J Proctor; Ian M Fearon Journal: BMC Public Health Date: 2017-08-22 Impact factor: 3.295
Authors: Sebastian Sailer; Giorgia Sebastiani; Vicente Andreu-Férnández; Oscar García-Algar Journal: Int J Environ Res Public Health Date: 2019-12-14 Impact factor: 3.390